PARIS–(BUSINESS WIRE)–Regulatory News:
Today Orano Med announced that it would be investing 15 million euros in
France and the United States to accelerate the development of
therapeutic solutions using the radioactive properties of lead-212 (212Pb)
in the fight against cancer. These investments will allow the expansion
of the technical production capacities of the two main Orano Med sites
in response to needs related to preclinincal and clinical development.
Lead-212 is a rare isotope produced by Orano Med that is used for a
series of treatments known as “targeted alpha therapy”, a promising
approach to fighting cancers with limited therapeutic options. This
approach uses the properties of alpha-emitters such as lead-212 to
specifically target and destroy the cancer cells, while limiting the
impact on healthy cells.
In practice, these investments will double the laboratory space
available at the Maurice Tubiana Laboratory in Bessines-sur-Gartempe
(France) in order to increase its lead-212 production capacities. They
will also finance the installation of a cleanroom, allowing the facility
to achieve the status of “pharmaceutical establishment” as recognized by
the French National Agency for the Safety of Medicines and Health
Products (ANSM), a necessary step before clinical doses can be sent for
therapeutic trials in Europe.
In the United States, the capacities of the Domestic Distribution &
Purification Unit (DDPU), located near Dallas, Texas, will be extended
to allow several clinical trials to be performed in parallel. New
research and development laboratories and the purchase of special
equipment for the development and synthesis of new molecules will also
accelerate Orano Med’s preclinical research into peptides1
radiolabeled with lead-212.
“We have reached a point where we are sufficiently confident in
the potential of our lead-212 therapies to make these investments, which
are vital to our development,” explained Julien Dodet, the CEO of
Orano Med, at the International Symposium on Targeted Alpha Therapy,
which took place this week in Ottawa. “They will enable us to
guarantee our supply of lead-212, and produce and ship clinical doses
for forthcoming trials, as well as strengthen our potential to develop
new molecules to enrich our portfolio of new therapies. The investment
program will run until mid-2020.”
Orano transforms nuclear materials so that they can be used to support
the development of society, first and foremost in the field of energy.
The group offers products and services with high added value throughout
the entire nuclear fuel cycle, from raw materials to waste treatment.
Its activities, from mining to dismantling, as well as in conversion,
enrichment, recycling, logistics and engineering, contribute to the
production of low-carbon electricity.
Orano and its 16,000 employees bring to bear their expertise and their
mastery of cutting-edge technology, as well as their permanent search
for innovation and unwavering dedication to safety, to serve their
customers in France and abroad.
Orano, giving nuclear energy its full value.
About Orano Med
Orano Med is a company that combines biotechnologies and nuclear
technology to develop new therapies in the fight against cancer. Orano
Med has developed a unique process to produce lead-212 (212Pb),
a rare metal used in targeted alpha therapy, an innovative and promising
approach in nuclear medicine that makes it possible to target and
destroy cancer cells while limiting the impact on surrounding healthy
cells. With its partners, Orano Med continues to develop effective
therapies that respond to patients’ needs.
More information on www.oranomed.com,
1 Peptides are chemical entities made up of amino acids, and
constitute one of the main sources of drugs on the current market. They
may be natural or produced through chemical synthesis, and are able to
bind to a target molecule (such as receptors specific to certain
cancers, for example).